Palvella Therapeutics (PVLA) Other Accumulated Expenses (2016 - 2024)
Historic Other Accumulated Expenses for Palvella Therapeutics (PVLA) over the last 12 years, with Q3 2024 value amounting to $1.0 million.
- Palvella Therapeutics' Other Accumulated Expenses rose 7930.43% to $1.0 million in Q3 2024 from the same period last year, while for Sep 2024 it was $1.0 million, marking a year-over-year increase of 7930.43%. This contributed to the annual value of $169000.0 for FY2023, which is 6501.04% down from last year.
- Palvella Therapeutics' Other Accumulated Expenses amounted to $1.0 million in Q3 2024, which was up 7930.43% from $1.0 million recorded in Q2 2024.
- Palvella Therapeutics' 5-year Other Accumulated Expenses high stood at $1.0 million for Q3 2024, and its period low was $169000.0 during Q4 2023.
- Over the past 5 years, Palvella Therapeutics' median Other Accumulated Expenses value was $497000.0 (recorded in 2023), while the average stood at $500947.4.
- Per our database at Business Quant, Palvella Therapeutics' Other Accumulated Expenses tumbled by 6722.85% in 2020 and then surged by 25260.12% in 2022.
- Quarter analysis of 5 years shows Palvella Therapeutics' Other Accumulated Expenses stood at $347000.0 in 2020, then grew by 13.26% to $393000.0 in 2021, then rose by 22.9% to $483000.0 in 2022, then plummeted by 65.01% to $169000.0 in 2023, then skyrocketed by 510.06% to $1.0 million in 2024.
- Its last three reported values are $1.0 million in Q3 2024, $1.0 million for Q2 2024, and $335000.0 during Q1 2024.